In light of the contradictory data that are currently available, more research is needed to establish whether patients receiving treatment with JAK inhibitors have an enhanced risk of developing lymphoma and, in the event that lymphoma is confirmed in additional validation studies, we need to know more about the risk estimates involved.
JAK inhibitors and risk of B-cell lymphomas.
Elisa Rumi
2019-01-01
Abstract
In light of the contradictory data that are currently available, more research is needed to establish whether patients receiving treatment with JAK inhibitors have an enhanced risk of developing lymphoma and, in the event that lymphoma is confirmed in additional validation studies, we need to know more about the risk estimates involved.File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
